Skip to main content

and
  1. Article

    Open Access

    Previous radiotherapy improves treatment responses and causes a trend toward longer time to progression among patients with immune checkpoint inhibitor-related adverse events

    Immune-related adverse events (irAEs) are frequently encountered by patients during immune checkpoint inhibitor (ICI) treatment and are associated with better treatment outcomes. The sequencing of radiotherapy...

    Anna Jokimäki, Henna Hietala, Jasmiini Lemma in Cancer Immunology, Immunotherapy (2023)

  2. Article

    Open Access

    Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients

    Anti-PD1 treatment has improved the survival of metastatic melanoma patients, yet it is unknown which patients benefit from the treatment. In this exploratory study, we aimed to understand the effects of anti-...

    Henna Kasanen, Micaela Hernberg, Siru Mäkelä in Cancer Immunology, Immunotherapy (2020)

  3. No Access

    Article

    Benefit of adjuvant interferon alfa-2b (IFN-α) therapy in melanoma patients with high serum MMP-8 levels

    Matrix metalloproteinases (MMPs) are important enzymes in tissue turnover and various inflammatory processes. In this study, it was evaluated whether serum MMP-8 can predict the response to adjuvant interfero...

    Pia Vihinen, Taina Tervahartiala, Timo Sorsa in Cancer Immunology, Immunotherapy (2015)